N2 neutrophils, novel players in brain inflammation after stroke: Modulation by the pparγ agonist rosiglitazone

Stroke

Volumn 44, Issue 12, 2013, Pages 3498-3508

  Cuartero, María Isabel ^a   Ballesteros, Iván ^a   Moraga, Ana ^a   Nombela, Florentino ^b   Vivancos, José ^b   Hamilton, John A ^c   Corbí, Ángel L ^d   Lizasoain, Ignacio ^a   Moro, María A ^a  

^a Facultad de Medicina   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

Author keywords

Immunomodulation; Inflammation; Phagocytosis

Indexed keywords

CD206 MANNOSE RECEPTOR; MANNOSE RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; UNCLASSIFIED DRUG; YM1 MANNOSE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CELL; BRAIN INFARCTION; BRAIN ISCHEMIA; BRAIN TISSUE; CELL MOTILITY; CELL PHAGOCYTOSIS; CELL SUSPENSION; CLEARANCE; CONTROLLED STUDY; ENCEPHALITIS; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MICROGLIA; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; N2 NEUTROPHIL; NEUROMODULATION; NEUROPROTECTION; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PHENOTYPE; POLARIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEREOMETRY; TREATMENT OUTCOME;

IMMUNOMODULATION; INFLAMMATION; PHAGOCYTOSIS;

BRAIN; ENCEPHALITIS; INFARCTION, MIDDLE CEREBRAL ARTERY; NEUROPROTECTIVE AGENTS; NEUTROPHILS; PPAR GAMMA; STROKE; THIAZOLIDINEDIONES;

EID: 84889251844     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.113.002470     Document Type: Article

References (45)

1. Jin R, Yang G, Li G. Inflammatory mechanisms in ischemic stroke: role of inflammatory cells. J Leukoc Biol. 2010;87:779-789.
2. Yilmaz G, Granger DN. Leukocyte recruitment and ischemic brain injury. Neuromolecular Med. 2010;12:193-204.
3. Kriz J. Inflammation in ischemic brain injury: timing is important. Crit Rev Neurobiol. 2006;18:145-157.
4. Segel GB, Halterman MW, Lichtman MA. The paradox of the neutrophil's role in tissue injury. J Leukoc Biol. 2011;89:359-372.
5. Mantovani A, Cassatella MA, Costantini C, Jaillon S. Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol. 2011;11:519-531.
6. al-Essa LY, Niwa M, Kohno K, Nozaki M, Tsurumi K. Heterogeneity of circulating and exudated polymorphonuclear leukocytes in superoxidegenerating response to cyclic AMP and cyclic AMP-elevating agents. Investigation of the underlying mechanism. Biochem Pharmacol. 1995;49:315-322.
7. Chakravarti A, Rusu D, Flamand N, Borgeat P, Poubelle PE. Reprogramming of a subpopulation of human blood neutrophils by prolonged exposure to cytokines. Lab Invest. 2009;89:1084-1099.
8. Puellmann K, Kaminski WE, Vogel M, Nebe CT, Schroeder J, Wolf H, et al. A variable immunoreceptor in a subpopulation of human neutrophils. Proc Natl Acad Sci U S A. 2006;103:14441-14446.
9. Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: N1 versus N2 TAN. Cancer Cell. 2009;16:183-194.
10. Tambuyzer BR, Ponsaerts P, Nouwen EJ. Microglia: gatekeepers of central nervous system immunology. J Leukoc Biol. 2009;85:352-370.
11. Perry VH, Nicoll JA, Holmes C. Microglia in neurodegenerative disease. Nat Rev Neurol. 2010;6:193-201.
12. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008;8:958-969.
13. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004;25:677-686.
14. Bouhlel MA, Derudas B, Rigamonti E, Dièvart R, Brozek J, Haulon S, et al. PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab. 2007;6:137-143.
15. Odegaard JI, Ricardo-Gonzalez RR, Goforth MH, Morel CR, Subramanian V, Mukundan L, et al. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature. 2007;447:1116-1120.
16. Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and functions. Immunity. 2010;32:593-604.
17. Allahtavakoli M, Shabanzadeh AP, Sadr SS, Parviz M, Djahanguiri B. Rosiglitazone, a peroxisome proliferator-activated receptor-gamma ligand, reduces infarction volume and neurological deficits in an embolic model of stroke. Clin Exp Pharmacol Physiol. 2006;33:1052-1058.
18. Collino M, Aragno M, Mastrocola R, Gallicchio M, Rosa AC, Dianzani C, et al. Modulation of the oxidative stress and inflammatory response by PPAR-gamma agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion. Eur J Pharmacol. 2006;530:70-80.
19. Pereira MP, Hurtado O, Cárdenas A, Alonso-Escolano D, Boscá L, Vivancos J, et al. The nonthiazolidinedione PPARgamma agonist L-796,449 is neuroprotective in experimental stroke. J Neuropathol Exp Neurol. 2005;64:797-805.
20. Pereira MP, Hurtado O, Cárdenas A, Boscá L, Castillo J, Dávalos A, et al. Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2 cause potent neuroprotection after experimental stroke through noncompletely overlapping mechanisms. J Cereb Blood Flow Metab. 2006;26:218-229.
21. Sobrado M, Pereira MP, Ballesteros I, Hurtado O, Fernández- López D, Pradillo JM, et al. Synthesis of lipoxin A4 by 5-lipoxygenase mediates PPARgamma-dependent, neuroprotective effects of rosiglitazone in experimental stroke. J Neurosci. 2009;29:3875-3884.
22. Tureyen K, Kapadia R, Bowen KK, Satriotomo I, Liang J, Feinstein DL, et al. Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents. J Neurochem. 2007;101:41-56.
23. Chu K, Lee ST, Koo JS, Jung KH, Kim EH, Sinn DI, et al. Peroxisome proliferator-activated receptor-gamma-agonist, rosiglitazone, promotes angiogenesis after focal cerebral ischemia. Brain Res. 2006;1093:208-218.
24. Luo Y, Yin W, Signore AP, Zhang F, Hong Z, Wang S, et al. Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. J Neurochem. 2006;97:435-448.
25. West MJ, Slomianka L, Gundersen HJ. Unbiased stereological estimation of the total number of neurons in thesubdivisions of the rat hippocampus using the optical fractionator. Anat Rec. 1991;231:482-497.
26. Denes A, Vidyasagar R, Feng J, Narvainen J, McColl BW, Kauppinen RA, et al. Proliferating resident microglia after focal cerebral ischaemia in mice. J Cereb Blood Flow Metab. 2007;27:1941-1953.
27. Houwen B. Blood film preparation and staining procedures. Clin Lab Med. 2002;22:1-14, v.
28. Enzmann G, Mysiorek C, Gorina R, Cheng YJ, Ghavampour S, Hannocks MJ, et al. The neurovascular unit as a selective barrier to polymorphonuclear granulocyte (PMN) infiltration into the brain after ischemic injury. Acta Neuropathol. 2013;125:395-412.
29. Murikinati S, Jüttler E, Keinert T, Ridder DA, Muhammad S, Waibler Z, et al. Activation of cannabinoid 2 receptors protects against cerebral ischemia by inhibiting neutrophil recruitment. FASEB J. 2010;24:788-798.
30. Mantovani A. The yin-yang of tumor-associated neutrophils. Cancer Cell. 2009;16:173-174.
31. Wang Q, Tang XN, Yenari MA. The inflammatory response in stroke. J Neuroimmunol. 2007;184:53-68.
32. del Zoppo GJ, Gorelick PB. Innate inflammation as the common pathway of risk factors leading to TIAs and stroke. Ann N Y Acad Sci. 2010;1207:8-10.
33. Nauseef WM. Myeloperoxidase deficiency. Hematol Oncol Clin North Am. 1988;2:135-158.
34. Reynolds WF, Rhees J, Maciejewski D, Paladino T, Sieburg H, Maki RA, et al. Myeloperoxidase polymorphism is associated with gender specific risk for Alzheimer's disease. Exp Neurol. 1999;155:31-41.
35. Green PS, Mendez AJ, Jacob JS, Crowley JR, Growdon W, Hyman BT, et al. Neuronal expression of myeloperoxidase is increased in Alzheimer's disease. J Neurochem. 2004;90:724-733.
36. Wang Q, Tang XN, Yenari MA. The inflammatory response in stroke. J Neuroimmunol. 2007;184:53-68.
37. Harbord M, Novelli M, Canas B, Power D, Davis C, Godovac-Zimmermann J, et al. Ym1 is a neutrophil granule protein that crystallizes in p47phox-deficient mice. J Biol Chem. 2002;277:5468-5475.
38. Hung SI, Chang AC, Kato I, Chang NC. Transient expression of Ym1, a heparin-binding lectin, during developmental hematopoiesis and inflammation. J Leukoc Biol. 2002;72:72-82.
39. Tada S, Okuno T, Yasui T, Nakatsuji Y, Sugimoto T, Kikutani H, et al. Deleterious effects of lymphocytes at the early stage of neurodegeneration in an animal model of amyotrophic lateral sclerosis. J Neuroinflammation. 2011;8:19.
40. Ponomarev ED, Maresz K, Tan Y, Dittel BN. CNS-derived interleukin-4 is essential for the regulation of autoimmune inflammation and induces a state of alternative activation in microglial cells. J Neurosci. 2007;27:10714-10721.
41. Ohtaki H, Ylostalo JH, Foraker JE, Robinson AP, Reger RL, Shioda S, et al. Stem/progenitor cells from bone marrow decrease neuronal death in global ischemia by modulation of inflammatory/immune responses. Proc Natl Acad Sci U S A. 2008;105:14638-14643.
42. Hawkes CA, McLaurin J. Selective targeting of perivascular macrophages for clearance of beta-amyloid in cerebral amyloid angiopathy. Proc Natl Acad Sci U S A. 2009;106:1261-1266.
43. Stienstra R, Duval C, Keshtkar S, van der Laak J, Kersten S, Müller M. Peroxisome proliferator-activated receptor gamma activation promotes infiltration of alternatively activated macrophages into adipose tissue. J Biol Chem. 2008;283:22620-22627.
44. Soehnlein O, Lindbom L. Phagocyte partnership during the onset and resolution of inflammation. Nat Rev Immunol. 2010;10:427-439.
45. Zhao X, Grotta J, Gonzales N, Aronowski J. Hematoma resolution as a therapeutic target: the role of microglia/macrophages. Stroke. 2009;40(3 suppl):S92-S94.